Dechra Pharmaceuticals PLC

Dechra Pharmaceuticals PLC

Annual Report and Accounts for the year ended 30 June 2012

The Evolution of Dechra

Your Questions Answered

by Ian Page

Watch The Video

Our Highlights

  • €135 million acquisition of Eurovet­­® Animal Health B.V. ("Eurovet") completed, funded by successful Rights Issue and debt re-financing
  • Strong performance from Pharmaceuticals in both Europe and the USA
  • NVS operating margin stabilised in second half

Our Highlights

  • Investment in product pipeline increased by 10%
  • Strong second half cash inflow resulted in a 92% full year conversion rate

Chairman's Statement

We remain confident that our strategy will continue to deliver future solid growth and enhanced Shareholder value

Find out more

Chief Executive's Review

Ian-page.jpg

The Group continues to progress its strategic objective of building a high margin, cash generative veterinary products business

Find out more

Financial Review

Operating profit for European Pharmaceuticals grew by 29.6% at constant currency with the operational leverage effect of higher pharmaceutical revenue being clearly demonstrated

Find out more

Highlights

Revenue

£ million

up 9.5%

Underlying Operating Profit*

£ million

up 15.0%

Underlying Profit Before Taxation*

£ million

up 9.6%

Underlying Earnings per Share*

pence

up 2.7%

Dividend per Share

pence

up 10.3%

Operating Profit

£ million

Profit Before Taxation

£ million

Earnings per Share

pence

Dechra is an international veterinary pharmaceutical business. Our expertise is in the development, manufacturing, distribution, sales and marketing of high quality products exclusively for veterinarians worldwide

We use cookies and track users anonymously, check this box and save to disable. We are inferring consent by continuing.